GSK’s (GSK) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of GSK (LON:GSK) in a research report report published on Wednesday morning,Digital Look reports. They currently have a GBX 1,900 target price on the stock.

A number of other equities analysts have also recently commented on GSK. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Citigroup lowered their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 price target on shares of GSK in a report on Tuesday, April 14th. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Finally, UBS Group restated a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of GBX 2,034.29.

GSK Price Performance

GSK stock opened at GBX 1,843 on Wednesday. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282. The business’s 50-day simple moving average is GBX 2,063.58 and its 200 day simple moving average is GBX 1,932.45. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The stock has a market cap of £73.57 billion, a price-to-earnings ratio of 12.97, a P/E/G ratio of 1.24 and a beta of 0.30.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The business had revenue of GBX 762.90 billion for the quarter. As a group, research analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In other GSK news, insider Luke Miels sold 15,579 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Also, insider Anne Beal purchased 196 shares of the stock in a transaction on Friday, March 20th. The shares were purchased at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Over the last ninety days, insiders have purchased 12,952 shares of company stock worth $26,850,952. 0.20% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.